Author:
Stadler M,Germing U,Kliche K-O,Josten K M,Kuse R,Hofmann W-K,Schrezenmeier H,Novotny J,Anders O,Eimermacher H,Verbeek W,Kreipe H-H,Heimpel H,Aul C,Ganser A
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference30 articles.
1. Ganser A, Hoelzer D . Clinical course of myelodysplastic syndromes. Hematol Oncol Clin N Am 1992; 6: 607–618.
2. Ganser A, Ottmann O, Seipelt G, Lindemann A, Hess U, Geissler G et al. Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia 1993; 7: 696–701.
3. Raza A, Mundle S, Shetty V, Alvi S, Chepra H, Span L et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996; 63: 265–278.
4. Deeg HJ, Beckham C, Loken MR, Bryant E, Lesnikova M, Shulman HM et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leukemia Lymphoma 2000; 37: 405–414.
5. Smith MA, Smith JG . The occurrence, subtype and significance of hematopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leukemia Res 1991; 5: 597–601.
Cited by
121 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献